Hsu Jerry, Brown Jeffrey, Mallick Adnan, Fara Michael, De Leacy Reade, Rosen Richard B, Ginsburg Robin N, Lema Gareth M C
Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, NY, USA.
Retina Center of New Jersey, North Bergen, NJ, USA.
J Vitreoretin Dis. 2024 Aug 8;8(5):622-626. doi: 10.1177/24741264241267376. eCollection 2024 Sep-Oct.
To describe the use of intra-arterial tissue plasminogen activator (tPA) to treat central retinal artery occlusion (CRAO). A case and its findings were analyzed. A 45-year-old man diagnosed with a CRAO and had cerebral angiography and treatment with intra-arterial tPA. After treatment, follow-up included optical coherence tomography (OCT), fundus photography, fluorescein angiography, and OCT angiography. The visual acuity (VA) improved from hand motions to 20/30 immediately after fibrinolysis. A vascular occlusion event the next day resulted in a decrease in VA to 20/400. After initiation of dual antiplatelet therapy, the patient's VA improved to 20/20. As the retina recovered, the evolution of retinal ischemic changes to a finding similar to paracentral acute middle maculopathy was seen on imaging. This is the first report describing a patient safely started on dual antiplatelet therapy that led to vision improvement after initial treatment with intra-arterial tPA for a CRAO resulted in recurrent vision loss.
描述动脉内使用组织型纤溶酶原激活剂(tPA)治疗视网膜中央动脉阻塞(CRAO)的情况。分析了1例病例及其检查结果。一名45岁男性被诊断为CRAO,并接受了脑血管造影及动脉内tPA治疗。治疗后,随访包括光学相干断层扫描(OCT)、眼底照相、荧光素血管造影和OCT血管造影。纤溶后视力(VA)立即从手动改善至20/30。次日发生血管阻塞事件,导致VA降至20/400。开始双联抗血小板治疗后,患者的VA改善至20/20。随着视网膜恢复,影像学检查显示视网膜缺血性改变演变为类似于中心旁急性黄斑病变的表现。这是第一份描述患者在动脉内tPA初始治疗CRAO导致视力反复丧失后安全开始双联抗血小板治疗并使视力改善的报告。